3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
97
Lung Neoplasms
35
Colorectal Neoplasms
35
Pancreatic Neoplasms
13
Adenocarcinoma of Lung
10
Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Colonic Neoplasms
7
Carcinoma, Renal Cell
7
Ovarian Neoplasms
6
Breast Neoplasms
6
Rectal Neoplasms
5
Melanoma
5
Endometrial Neoplasms
5
Stomach Neoplasms
4
Adenocarcinoma, Bronchiolo-Alveolar
4
Triple Negative Breast Neoplasms
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Sarcoma
2
Salivary Gland Neoplasms
2
Recurrence
2
Pleural Effusion, Malignant
2
Esthesioneuroblastoma, Olfactory
2
Carcinoma, Pancreatic Ductal
2
Interventions
Vinorelbine
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metatropic dwarfism
×
Cetuximab
×
Thoracic
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts